Intrathecal cytarabine

ApprovedSmall molecule

Pacira Pharmaceuticals, Inc

Intrathecal cytarabine is one of 127 small molecule programs targeting Lymphoma. It is currently in Approved.

Indications

Total Trials

Active Trials

126

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

LeukemiaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

MeningitisActive, not recruiting

LymphomaPhase 2

Active, not recruiting

LeukemiaPhase 2

Active, not recruiting

Acute Myeloid LeukemiaPhase 1

Active, not recruiting

MeningitisApproved

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Intrathecal cytarabine

Pacira Pharmaceuticals, Inc

Approved

1 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Oncaspar

SServier

Preclinical

15 4

Norvir

AbbVie

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphoma1 trial

SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00002571·52 enrolled

Acute Lymphoblastic Leukemia1 trial

Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL

Unknown status·SSun Yat-sen University·Phase 2·NCT02660762·100 enrolled

Acute Myeloid Leukemia1 trial

Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia

Withdrawn·EEmory University·Phase 1·NCT02680951

Leukemia1 trial

Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

Terminated·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 2·NCT01158885·2 enrolled

Meningitis1 trial

DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor

Completed· Pacira Pharmaceuticals, Inc logo

Pacira Pharmaceuticals, Inc·Phase 4·NCT00029523·100 enrolled

1 more indication

Relapsed or Refractory1 trial

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

Completed·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT01861002·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Intrathecal cytarabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intrathecal cytarabine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intrathecal cytarabine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pacira Pharmaceuticals, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Pacira Pharmaceuticals, Inc

Intrathecal cytarabine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphoma1 trial

Acute Lymphoblastic Leukemia1 trial

Acute Myeloid Leukemia1 trial

Leukemia1 trial

Meningitis1 trial

Relapsed or Refractory1 trial

References

Drug Info

Quick Facts

Related News